VetCell Therapeutics Begins Production of Advanced Cell Therapies for Dogs with OA
ReGen OA is a stem cell therapy that treats symptoms of OA and can potentially regenerate damaged tissues, EvoluGen OA is a drug-free cell therapy for treating symptoms of osteoarthritis
SANTA ANA, Calif., March 7, 2016 – VetCell Therapeutics, a pet-focused subsidiary of PrimeGen Biotech, a pioneer in the research and discovery of practical therapeutic uses for stem cells, today announced that it has begun production of two advanced cell therapies, ReGen OA™ and EvoluGen OA™. These autologous cell based products are manufactured specifically for vets treating dogs diagnosed with osteoarthritis. VetCell Therapeutics is partnering with veterinarians to help commercialize autologous stem cell and blood-based cell therapies for their patients’ specific needs.
VetCell Therapeutics’ current cell therapy options for dogs with OA include:
- ReGen OA™ is an autologous stem cell therapy for treating canine OA derived from the stromal vascular fraction (SVF) of processed subcutaneous or abdominal adipose tissue. Administered as an intra-articular injection, the cells that make up ReGen OA have shown to be an effective and safe therapy for treating pain and inflammation caused by OA. In published cases, the cells in SVF have the potential to regenerate tissues damaged by OA, and patients may experience relief with just one treatment.
- EvoluGen OA™ is a drug-free alternative autologous cell treatment that utilizes platelet rich plasma (PRP) derived from the canine patient’s blood. Administered as an intra-articular injection, EvoluGen OA is developed to reduce mild to advanced symptoms of OA within the affected joint. The PRP contained within EvoluGen OA is validated and has a defined platelet concentration that is rich with beneficial growth factors that can reduce OA symptoms and trigger a healing response within the body. Platelet rich plasma has shown promising signs of being able to slow the progression of joint degeneration in canine OA patients.
“Canine OA is an extremely painful disease that unfortunately only gets worse with time if left untreated,” said Dr. Chad Maki DVM, Chief Medical Officer at VetCell Therapeutics. “Even though stem cell therapies designed to treat the symptoms and potentially reverse damage caused by the disease have been around for more than a decade, the number of suppliers has remained very low and production cost markup has left available therapies very expensive. At VetCell Therapeutics, we aim to make high-quality stem cell therapies readily available to veterinary clinics and affordable for their patients.”
VetCell Therapeutics’ patented and patent pending regenerative medicines include cell therapies for sick and aging animals based on stem cells derived from adipose tissue. These therapies have the potential to treat a wide range of ailments, including severe pain and inflammation resulting from various degenerative osteoarthritic conditions to organ failure and autoimmune diseases. VetCell Therapeutics is enlisting the collaboration of veterinarians worldwide to make stem cell therapies a prevalent and trusted treatment for many diseases, including canine OA. Using state-of-the-art research laboratories, the scientists at VetCell Therapeutics are continuously investigating future cell-based therapies utilizing allogeneic and autologous stem cells derived from sources other than adipose tissue, like bone marrow, blood and organ tissues.
“Spanning two decades, our research has led to some significant discoveries in the therapeutic properties of stem cells for combating the effects of various debilitating diseases,” said Tom Yuen, CEO of PrimeGen Biotech, LLC. “We are excited to now offer cell treatments for pets based on our research and patents, and are actively working with veterinarians around the world to ensure that their patients’ families have access to affordable, high-quality stem cell therapies.”
In addition to cell therapy development, VetCell Therapeutics’ value-add services to veterinarians include cryo-banking of cells for later use and culturing or growing fresh cells for retreatment which eliminates the need for pets to withstand multiple tissue biopsies. VetCell Therapeutics therapies are developed in a certified ISO 7 cleanroom in accordance with the FDA’s Current Good Manufacturing Practice (cGMP) regulations, ensuring a safe and high-quality product for clinical use.
To learn more about VetCell Therapeutics and the company’s product offering, please visit www.vetcelltherapeutics.com. To learn more about PrimeGen Biotech and its research, please visit www.primegenbiotech.com.
# # #
About VetCell Therapeutics:
VetCell Therapeutics is a cell therapy manufacturer focused on generating and delivering cell-based treatments for use in veterinary practices. We believe we can help our animal companions who suffer from debilitating medical conditions live a pain-free life without harsh drugs. There are various degenerative conditions that affect animals, causing them pain and discomfort, and traditional drug and surgical treatments often fall short of offering long-term treatment of the associated symptoms. VCT recognizes that cell-based therapies are becoming more commonplace and effective for improving the well-being of pets. Our mission is to develop the highest-quality cell-based therapies for ailing pet companions to provide them a better quality of life.
PrimeGen Biotech LLC:
Founded in 2002, PrimeGen Biotech is a privately-held research firm dedicated to discovering the best possible applications for stem cell therapies and translating its research into effective therapeutic applications. PrimeGen Biotech is located in Santa Ana, California and operates a 10,000 sq. ft. facility. The newly renovated facility consists of a certified ISO 7 clean room and modern laboratories capable of cell processing, cell culture, molecular biology, flow cytometry, and histology. The laboratories are designed specifically to meet the requirements of our unique research approaches. The PrimeGen team includes research scientists and specialists with decades’ experience researching adult stem cells.